Podcasts about Jarvik

Today I'm going to talk about 7 mistakes I made, and that you might be making that will hinder your healing by keep you focused on fixing your body or avoiding perceived triggers.Here is the perceived food intolerance study:Monsbakken, K. W., Vandvik, P. O., & Farup, P. G. (2006). Perceived food intolerance in subjects with irritable bowel syndrome-- etiology, prevalence and consequences. European journal of clinical nutrition, 60(5), 667–672. https://doi.org/10.1038/sj.ejcn.1602367Here is the back normal abnormalities study:Brinjikji, W., Luetmer, P. H., Comstock, B., Bresnahan, B. W., Chen, L. E., Deyo, R. A., Halabi, S., Turner, J. A., Avins, A. L., James, K., Wald, J. T., Kallmes, D. F., & Jarvik, J. G. (2015). Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. AJNR. American journal of neuroradiology, 36(4), 811–816. https://doi.org/10.3174/ajnr.A4173

It's time for a spot of piracy for our intrepid and newly-aimless adventurers. And where better to do that than on a deadly planet infested with enormous zeppelin-arsed insects? But who died and made Tarrant Liberator captain? Is Jarvik a complete arse (or merely a buttock)? As Servalan is unqualified to weep at the death of a friend, does laughing at the demise of an enemy count? And did the episode yield riches for Jim and Martin, or was it just some obsolete space junk? Listen to find out! This episode can also be found at iTunes/Apple Podcasts, Spotify, Audible, Player FM, Pocket Casts, Podvine, Castbox and all other pod apps (as far as we know). You can also find us on Facebook, Mastodon at @mutoidpodcast@mstdn.social, and on Threads and Bluesky where we are @mutoidkrynoidpods. Thanks for listening! And, as promised within the podcast, the Clive James hatchet job and TV spot with Jacqueline Pearce. https://archive.clivejames.com/essays/facedog.htm https://www.youtube.com/watch?v=LvxBCAdMoD0  

How the fossil teeth of an 11-year old helps us understand why humans have an unusually long childhood and one town in Scotland will have a jolt to its budget after discovering a 300-year-old statue. that was being used as a doorstop, is valued at $2M USD. Plus, on This Day in History; Bill Schroeder makes history with the Jarvik-7 artificial heart. These Fossil Teeth From an 11-Year-Old Reveal Clues to Why Humans Developed an Unusually Long Childhood | Smithsonian Did long childhood shape the evolution of the human brain? | Knowridge The secrets of fossil teeth revealed by the synchrotron: A long childhood is the prelude to the evolution of a large brain | ScienceDaily Dental evidence for extended growth in early Homo from Dmanisi | Nature Town Gets Go Ahead to Sell 300-Year-old Marble Bust Found Propping Open a Shed–And Worth $2 Million Bill Schroeder lived 620 days with an artificial heart Bill Schroeder made medical history with artificial heart implant in ‘80s - YouTube Jarvik-7 Artificial Heart | Smithsonian Institution Contact the show - coolstuffcommute@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Whiskey: Old St. Andrew's Clubhouse Scotch in miniature golf ball decanters Wormholes: Sue and Shavonne join us for only our second Wormhole episode ever! • Ed puts out Shavonne's business (but it's for her own protection) • Sue and this whisky were born in the same year (1969 *wink*) • #doublegroan • Golf has been annoying wives for six centuries • Ed's brother and his housemate are just friends (like Scott & Ed and Bert & Ernie) • The St. Andrew's packaging is like an old Christmas ornament box • Apparently “old men in white shorts” is a nosing note now • Ed's appropriate for once • Gasoline has had the lowest percentage price increase since 1982 • Today's stock market has grown 38 times what it was • Shavonne was drinking whiskey at 3 and Scott was doing coke at 14 • Wait, John Hinckley is on social media?! • The Tylenol scare changed drug packaging forever • Shavonne shades Ed • We don't talk about Jarvik 1 through 6 • Sue won a “Who Shot JR?” contest • Ed does a solid Nick Nolte impression • Ed's being a killjoy (but gets overruled by the ladies being annoying) • Scott has the Rick Springfield box set • 1982 wasn't really a great year for music Music Credits: Political Action Ad, Ouroboros, and The Pyre by Kevin MacLeod | Link: https://incompetech.filmmusic.io | License: http://creativecommons.org/licenses/by/4.0

Episode 137: Heart Transplant and LVADFuture Doctor My explains two treatments for advanced heart failure, heart transplant and Left Ventricle Assist Device (LAVD). Dr. Arreaza adds historical information about the first artificial heart implant and the first LAVD.  Written by My Chau Nguyen, MSIV, American University of the Caribbean School of Medicine. Comments by Hector Arreaza, MD.  You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Introduction: Advanced heart failure is a major concern in the United States. Heart failure has a high 1-year mortality average of 33%. Although medical therapies have improved survival rates, some patients with progressive and advanced heart failure may still require heart transplantation or mechanical support such as left ventricular assist devices (LVADs) to prolong survival and improve quality of life.It is estimated that 23 million people in the world have heart failure, and many of them are in end-stage heart failure. When it comes to treating severe heart failure, there are two main options: heart transplantation and left ventricular assist devices (LVADs). Heart transplant: The operation to perform a heart transplant typically lasts between five to six hours but may take longer in patients who have undergone previous open-heart surgery or have an LVAD in place. However, because donors' hearts are a scarce resource, not all patients are eligible for transplantation. The following are absolute indications for referral for Heart Transplant listing:Cardiogenic shock requiring continuous intravenous inotropic therapy (i.e., dobutamine, milrinone, etc.) or circulatory support with intra-aortic balloon pump counterpulsation devices or left ventricular assist device (LVAD) to maintain adequate organ perfusion.Peak oxygen consumption VO2 (VO2max) less than 10 mL/kg per minute.New York Heart Association NYHA class III or IV despite maximized medical and resynchronization therapy.Recurrent life-threatening arrhythmias unresponsive to medical therapy such as an implantable cardiac defibrillator, medical therapy, or catheter ablation.End-stage congenital heart failure with no evidence of pulmonary hypertension.Refractory severe angina without potential medical or surgical therapeutic options.Selected patients with restrictive and hypertrophic cardiomyopathies.My experience with a heart transplant: I consider myself extremely fortunate for witnessing the whole complex procedure involved in lung and heart transplantation at Jackson Memorial Hospital in Miami, FL. It was an incredible experience to join the transplant team in retrieving a donor organ. Timing plays a critical role in heart transplants. When a suitable donor becomes available, every second counts. We must quickly arrange transport and secure an operating room. It is essential that the distance between the donor and the hospital is within our designated region. For example, we are in Region 5, including Arizona, California, Nevada, New Mexico, and Utah. Once everything is in order, we divide into two teams. One team sets off to retrieve the donor while the other prepares the patient in the operating room. It is a race against time, as hearts and lungs must be transplanted within approximately four hours of removal from the donor. It was remarkable to see how everything was so precisely scheduled, from the arrival and departure of the teams to the transplantation of the organs. It is an inspiring experience to witness these life-saving procedures in action.History of the artificial heart.Arreaza: It is great to hear about your experience, but we know that not everyone can have a heart transplant. So, let us talk about other options. For example, an artificial heart. I lived in Utah for several years and I heard something about the first artificial heart being implanted there, so here is the information. William DeVries was the surgeon who led the implantation of the first artificial heart, the Jarvik-7, at the University of Utah on December 1, 1982. The patient was a retired dentist, Barney Bailey Clark, who survived 112 days connected to the device. Today, the modern version of the Jarvik-7 is known as the SynCardia temporary Total Artificial Heart. It has been implanted in more than 1,350 people as a bridge to transplantation.Left Ventricular Assist Device (LVAD):In recent years, LVADs have become increasingly popular as a viable alternative to transplantation, as they have demonstrated improved durability by using wear-free components, greatly improving mortality rates in heart failure patients. Arreaza: The first left ventricular assist device (LVAD) system was created by Domingo Liotta at Baylor College of Medicine in Houston, Texas, in 1962. It is basically a pump that is used for patients who are on end-stage heart failure. The LVAD is surgically implanted, it is a battery-operated pump that helps the left ventricle pump blood to the rest of the body. LVADs can be used as a temporary treatment while patients are waiting for a transplant. It is called a “bridge-to-transplant therapy”. In some cases, an LVAD may restore a failing heart and eliminate the need for a transplant. An LAVD may also be used as a “destination therapy” in patients who are not candidates for heart transplants. LVAD can prolong and improve patients' quality of life.My: The purpose of an LVAD is to support patients with heart failure by increasing perfusion and reducing filling pressures in the heart. It is important to note, however, that LVADs only partially assist the pumping action of the diseased ventricle and cannot fully replace the function of the heart. Therefore, the decision to have an LVAD or heart transplant must be taken after careful discussion between the patient and the cardiologist to determine which option is best to reach the patient's goals of care.Example of an LVAD:Recently, The Berlin Heart Ventricular Assist Device (VAD) has been a game-changer in saving children with severe heart conditions. As you may guess from the name, it is developed in Germany. It is recently approved by US FDA in 2011. This type of LVAD has been used in approximately 1,000 children worldwide, including 12 cases in the United States. The Berlin Heart is a simple air-driven pump that takes over the work of one or both sides of a child's own heart. It pumps blood around the body to keep the brain and other organs healthy, allowing the child to grow and get stronger. The use of this device is required until the child is transplanted, or for a small number of children until their own heart recovers. I once again had the privilege of witnessing the procedure performed by one of the inventors, my preceptor, Dr. Loebe in the NICU at Jackson Memorial Hospital.Conclusion: Now we conclude episode number 137, “Heart Transplant and LVAD.” My explained two options for the treatment of advanced heart failure: Heart transplant and Left Ventricular Assist Device, or LVAD. She shared her recent experience in her surgery rotation at Jackson Memorial Hospital. Dr. Arreaza added the history of the first artificial heart implanted in Utah and the first LAVD. We hope you enjoyed it.This week we thank Hector Arreaza, and future doctor My Chau Nguyen. Audio editing by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________Sources:Theochari CA, Michalopoulos G, Oikonomou EK, Giannopoulos S, Doulamis IP, Villela MA, Kokkinidis DG. Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality: a systematic review and meta-analysis. Ann Cardiothorac Surg. 2018 Jan;7(1):3-11. doi: 10.21037/acs.2017.09.18. PMID: 29492379; PMCID: PMC5827119. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827119/.Alraies MC, Eckman P. Adult heart transplant: indications and outcomes. J Thorac Dis. 2014 Aug;6(8):1120-8. doi: 10.3978/j.issn.2072-1439.2014.06.44. PMID: 25132979; PMCID: PMC4133547. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133547/.Birks, E. J., & Mancini, D. (2022, November 9). Treatment of advanced heart failure with a durable mechanical circulatory support device. UpToDate. Retrieved April 21, 2023. https://www.uptodate.com/contents/treatment-of-advanced-heart-failure-with-a-durable-mechanical-circulatory-support-device.Drews T, Loebe M, Hennig E, Kaufmann F, Müller J, Hetzer R. The ‘Berlin Heart' assist device. Perfusion. 2000;15(4):387-396. doi:10.1177/026765910001500417.Middleton, J. (2021, August 26). What is the time frame for transplanting organs? Donor Alliance. Retrieved April 21, 2023, from https://www.donoralliance.org/newsroom/donation-essentials/what-is-the-time-frame-for-transplanting-organs/.The Bridge to Transplant Team, The Child and Family Information Group. (2017, July). Berlin Heart Mechanical Heart Assist. NHS choices. Retrieved April 21, 2023, from https://www.gosh.nhs.uk/conditions-and-treatments/procedures-and-treatments/berlin-heart-mechanical-heart-assist/.Royalty-free music used for this episode: "Tempting Tango." Downloaded on October 13, 2022, from https://www.videvo.net/

Welcome to the Instant Trivia podcast episode 697, where we ask the best trivia on the Internet. Round 1. Category: All Things Golden 1: In a fable, a farmer discovers that this bird lays golden eggs. a hen (or a goose). 2: The American Society of Civil Engineers chose this landmark as one of the 7 wonders of the modern world. the Golden Gate Bridge. 3: Happy golden anniversary! Congratulations on this many years of marriage. 50. 4: According to the AKC, in 2013 it was the third most popular breed of dog. golden retriever. 5: In Exodus 32 he fashions a golden calf. Aaron. Round 2. Category: Beverages 1: This brand's Cranberry Juice Cocktail first appeared in 1933. Ocean Spray. 2: Alpine mountains appear on the label of this ConAgra brand of hot cocoa. Swiss Miss. 3: Back in 1898 a guy named Edward created this biting "olde tyme" root beer. Barq's. 4: This juice brand calls itself "100% pure squeezed Florida sunshine". Tropicana. 5: This soft drink once used the slogan "It'll tickle yore innards". Mountain Dew. Round 3. Category: Lewis Or Clark 1: In 1982 Barney Clark got the first permanent, completely artificial one of these organs, the Jarvik-7. a heart. 2: Between 1981 and 1991 he won 65 consecutive long jump competitions. Carl Lewis. 3: In 1994 James H. Clark co-founded this company known for its Navigator web browser. Netscape. 4: Chemist Gilbert Lewis suggested that a chemical bond involves 2 atoms sharing a pair of these, as in a covalent bond. electrons. 5: This pen name was made by Latinizing the author's 1st 2 names, reversing their order and then translating them back to English. Lewis Carroll. Round 4. Category: Quotes/ Magazines 1: In a song by The Temptations: "Papa was a blank blank ". rollin' stone. 2: The movie "Network": "I'm as blank as hell, and I'm not going to take this anymore!". mad. 3: Ecclesiastes: "To every thing there is a season, and a blank to every purpose under heaven". time. 4: Alcuin: "The voice of the blank is the voice of God". people. 5: The mirror from Disney's "Snow White": "Lips red as the rose, hair black as blank ". ebony. Round 5. Category: Put On Your Disco Shoes 1: This group with a construction worker, cop, G.I., cowboy and Indian sang "San Francisco (You've Got Me)". The Village People. 2: "I'm Your Boogie Man" by KC and this group hit No. 1, but their "Boogie Shoes" could only dance to No. 35. the Sunshine Band. 3: To everything there is a season: the first Top 40 hit for this "Queen of Disco" was "Love To Love You Baby". Donna Summer. 4: The Trammps wanted to "burn that mother down" with this song from "Saturday Night Fever". "Disco Inferno". 5: Don't "Freak Out", but Queen's "Another One Bites The Dust" has a bass line similar to "Good Times" by this "stylish" band. Chic. Thanks for listening! Come back tomorrow for more exciting trivia! Special thanks to https://blog.feedspot.com/trivia_podcasts/

We open this segment with the music of Steve Gunn, one of the artists featured in a recent episode of Essential Tremors,a terrific and very popular podcast from WYPR's Podcast Central that explores the musical influences of composers and performers across a full spectrum of musical genres. The podcast debuted in 2018, and it's just dropped its 50th episode. Joining Tom now to talk about the podcast's concept, and how it's worked for the past three-plus years, are Essential Tremors' creators and co-hosts: Matt Byars is the drummer and sound processor in the DC-based band The Caribbean, and plays as Attorneys General and The Jarvik 6; he is also a middle school English teacher. He was previously a contributor to WYPR's “The Signal.” Matt was raised in Kentucky and has lived in Baltimore since the mid-1990s. Lee Gardner has been a professional journalist and music writer for more than 25 years. He's the former music editor, and editor in chief, of Baltimore City Paper. Lee is currently a senior reporter at The Chronicle of Higher Education in Washington, DC. His writing has appeared in or on The Wire, Newmusicbox, Nylon, National Public Radio, and numerous altweeklies. He was born in Tennessee. Lee Gardner and Matt Byars join us on Zoom from Baltimore. Essential Tremors streams on WYPR's Podcast Central and other platforms. It's alsobroadcast on WYPR on the second Sunday of every month at 7:00 PM on 88.1 FM and at wypr.org.  See omnystudio.com/listener for privacy information.

 Find out how our conscious awareness can affect how we productively operate in life and in our business Learn more on why you shouldn't be too attached to your plans not unless it is worthy of your life and time Understand why knowing “how” beforehand is an overrated statement and excuse that you should stop thinking Resources/Links: Wanting to Learn How to Live a Rich Life But Those Limiting Thoughts Keep on Stopping You? Find out how to turn your business into a massive empire with the power of your mindset: Paulmartinelli.net Summary Have you been feeling down in the dumps and just feel like you can't get to the top of your business dreams? Do you want to learn how to change those limiting beliefs and thoughts into powerful action and growth? Are you ready to live the rich life you have ever so deserved? Paul Martinelli is an internationally acclaimed speaker, trainer, mentor, and coach who truly believes that if you can dream it, you can do it. In this episode, Paul talks about why you should be ditching the idea of knowing “how” to do things and start thinking about the “why”. He also shares his insights on how you can activate your full potential through the right mindset and grow and live rich! Check out these episode highlights: 01:00 – Paul's ideal client: “Nice, happy, rich people. I want to work with people who are nice, people who are happy, and people who are not going to beat me up on price and who have a vision, who want to be, do and have more in their life.” 01:20 – Problem Paul helps solve: “I think what I do is I interrupt the story. You know, everybody wants to be, do, and have more. It's who we are as a spirit to beat. And there's a story that interrupts us seeking out, living our full potential.” 02:22 – Typical symptoms that clients do before reaching out to Paul: “Look, there are seven levels of conscious awareness, how we think, and make decisions in our lives. And when we operate from the lower levels of conscious awareness, we're bound to screw things up.” 03:47 – Common mistakes that people make before they find Paul's solution: “They think in reverse. They look at their results, and they allow their results to be the cause of their lives. “I can't have my dream…” because of these results: because they don't have the time, because they don't have the money.” 05:04 – Paul's Valuable Free Action (VFA): “'How' is overrated. The Wright brothers didn't have a pilot's license. They didn't know how to build it. They didn't know how to fly it. Once they got it in the air, they did not know how to land it.” 06:07 – Paul's Valuable Free Resource (VFR): Check out Paul's Website: Paulmartinelli.net 06:39 – Q: What's the biggest mistake people make when they set goals? A: I'll give you three or four of them. I think one of the things is that you know, we plan too much, and then we fall in love with the plan. You're a creative being and where your focus goes, your energy flows. Tweetable Takeaways from this Episode: “We were designed to be causative. Not to live on the side of effects of our lives, but to be the cause.” -Paul MartinelliClick To TweetTranscript (Note, this was transcribed using a transcription software and may not reflect the exact words used in the podcast) Tom Poland 00:10 Welcome, everyone, to another edition of Marketing the Invisible. My name is Tom Poland beaming out to you from little Castaways Beach in Queensland, Australia, joined today by Paul Martinelli. Paul, good day. A very warm welcome from down under. Sir, where are you based? Paul Martinelli 00:23 I'm in Jupiter, Florida, just about an hour and a half north of Miami. Tom Poland 00:27 Perfect, and I think you said two hours south of Mickey Mouse. Is that right? Paul Martinelli 00:31 You bet! Absolutely. Tom Poland 00:33 For those of you who don't know Paul, he's an internationally acclaimed speaker, trainer, mentor, and coach who truly believes that if you can dream it, you can do it. He's also known as the assassin of self-limiting beliefs which brings us, Paul, nicely to the title of this interview, which is, “How to Break the Invisible Boundary of Limiting Self Beliefs”. Paul is going to share with us how to do that in just seven minutes. Paul, thank you for rocking up. Our time starts now, sir. Question number one is who is your ideal client? Paul Martinelli 01:00 Nice, happy, rich people. I want to work with people who are nice, people who are happy, and people who are not going to beat me up on price and who have a vision, who want to be, do and have more in their life. Tom Poland 01:13 Perfect! So question number two, thank you for that. Very succinct. What's the problem you solve for the happy, nice, rich people? Paul Martinelli 01:20 I think what I do is I interrupt the story. You know, everybody wants to be, do, and have more. It's who we are as a spirit to beat. And there's a story that interrupts us seeking out, living our full potential. Now that story could be like mine. I'm a high school dropout. I'll never amount to anything. Now, I went on to generate, you know, three-quarters of a billion dollars worth of sales in five multimillion-dollar companies. So the story is not the truth. And so when I think I'm probably the very best in the world at doing is helping people think differently, challenging the boundary that they've set for themselves on income, on relationship, on health, on happiness, on whatever it is. We can be, do and have much more than the results of our life we indicate we can have. Tom Poland 02:07 Perfect, thank you for that. Paul, six minutes left. Question number three is what are the typical symptoms that these folks are going to be experiencing? What's going on in their life or their business or their relationships or in their head that they think, “Well, gee, I need to find out more about what Paul's up to”? Paul Martinelli 02:22 Look, there are seven levels of conscious awareness, how we think, and make decisions in our lives. And when we operate from the lower levels of conscious awareness, we're bound to screw things up. So the lowest level of awareness, symptoms of people are, you know, they're blaming other people. “See what you made me do”, “He made me mad”, “They upset me”, “It's the boss's fault, the economy's fault, government's faults.” Everybody else's fault, but you. So it's people who know in their heart, they know in their heart, that they haven't really stepped into the full responsibility of their life. And they're living at this fourth level of awareness, which is “aspiration”. This is where they aspire to be, do, and have things, but they never get around to it. “One of these days, I'm gonna..” “I'm going to spend time with my family”, “I'm going to go to church”, “I'm going to start the business”, “I'm going to go back to school”, “I'm going to learn a different language.” They speak the language of aspiration. And what's worse is they've built a network of people who make it safe for them to quit. Who says they're sorry, “Hey, you gave it a good shot”, “Hey, you give it a good shot.” So you know, the symptoms for me is, if everything's the same if people who know you and haven't seen you for a year come up to you and say, “Geez, you haven't changed a bit!” That's a problem. Tom Poland 03:34 Well said. Alright, thank you, sir! We've got- let's go to question number four, and we got four minutes left. What are some of the common mistakes that people make when they're trying to break out of the rut that they're in, these self-limiting beliefs? What would you say are some of the biggest mistakes they make? Paul Martinelli 03:47 They think in reverse. They look at their results, and they allow their results to be the cause of their lives. “I can't have my dream…” because of these results: because they don't have the time, because they don't have the money, because they don't have the support, because my wife doesn't believe in me. Because, because, because! Emerson said that the law of all laws is the law of cause and effect, and in a universe governed by creative force. And we are, as far as we know, we are the only intelligent species that can create beyond our conditions and circumstances. We were designed to be causative. Not to live on the side of effects of our lives, but to be the cause. And the mistake people make is they look at their results. And they think their results are an indication of their potential. It's a reflection of their awareness of their potential. And as they expand the awareness of their true, infinite, God-given potential, then they have the belief that drives the behavior to change the result. Stop thinking in reverse! Tom Poland 04:50 Inspirational stuff, and so true too! So thank you for that, sir. Three minutes left. And question number five. Let's talk about a top tip, kind of like a valuable free action, probably not going to solve the whole problem of folks, but it might take them a step in the right direction? Paul Martinelli 05:04 Look, “how” is overrated. The Wright brothers didn't have a pilot's license. They didn't know how to build it. They didn't know how to fly it. Once they got it in the air, they did not know how to land it. So if you think you're going to need to know how to do whatever it is that you want to do, perish the thought! You don't know how to do anything. You don't even know how to stand up out of the chair. If what you would do is you would start to move and you tell me what you did. You don't know how to do anything. The model is very simple– try and fail and learn. Try and fail and learn! And so if I could give one piece of advice is understand that “how” is over related. You don't need to know how, you need to know why. See, Saul didn't know how, he knew why. Jarvik didn't know how, he knew why. Edison didn't know how, he knew why. Tom Poland 05:53 And figured it out along the way. Paul Martinelli 05:55 You bet. Tom Poland 05:56 Thank you, sir. Question six, let's give people a valuable free resource. Where can folks go to find out more about your work and more inspiration, more ideas for moving forward? Paul Martinelli 06:07 Thanks so much. The easiest thing is to go to my website, Paulmartinelli.net. And sign up for my free daily thought that puts you on my mailing list. And I'm always releasing free stuff. Or go check out my YouTube channel, Paul Martinelli, there are all kinds of free content there! Tom Poland 06:23 And, folks, Martinelli is M-A-R-T-I-N, Martin, E, double L, I. So Paulmartinelli.net, or the YouTube channel. Thank you for that, sir. 70 seconds left, heaps of time. Question number seven, what's the one question I should have asked you but didn't? Paul Martinelli 06:39 I think what's the biggest mistake when people make when they set goals? I'll give you three or four of them. I think one of the things is that you know, we plan too much, and then we fall in love with the plan. You're a creative being and where your focus goes, your energy flows. And if all of your passion and energy is attached to a plan, the Buddhist religion tells us that the source of all suffering is attachment. If we become attached to the plan, and the plan starts to fail, we surrender the goal. We lower the goal to match the plan. Another mistake is we think that the goal is so worthy, that this is some high aspiration, and we fail to recognize that you're going to trade your life for it. It had better be a worthy goal. It's not whether you're worthy of the goal. Is the goal worthy of you? Because if it's not, you will pay the price. Last, you don't need to get the goal. You've already got it! Tom Poland 07:33 Paul Martinelli, thank you so much for your time. Paul Martinelli 07:36 You're welcome. Tom Poland 07:38 Thanks for checking out our Marketing The Invisible podcast. If you like what we're doing here please head over to iTunes to subscribe, rate us, and leave us a review. It's very much appreciated. And if you want to generate five fresh leads in just five hours then check out www.fivehourchallenge.com.

Kate Jarvik Birch is a full-time visual artist, author, playwright, and daydreamer. Her art has been featured worldwide in stores like Target, Pier One, and World Market, as well as in television series and major motion pictures such as Transparent, Medium, Glee, Twenty-One Jump Street, and Looper. She graduated with a degree in Painting and Drawing from the University of Utah in 2005 and lives and works in Salt Lake City, Utah.

In this episode I get to chat with Tanya Jarvik, a speaker and relationship coach who shares her story about navigating non-monogamy in the mid-90s, before any of the major books and authors we know and love today, were available or published. Tune in to hear her story about telling her husband that she had a new love interest after years of monogamy, how she began to build community through magazines and online communities, and what it takes to make our communities strong and vibrant today. We also get to hear her experience of growing up in a Mormon household and what role religion played in her discovery of and journey through non-monogamy and polyamory. We also get to learn a new term, coined by Tanya herself, as how she identifies as a Relationship Permaculturalist. Tune in to learn what that means and see if it resonates with you! Learn more about Tanya at www.radicallyrooted.com! --- Support this podcast: https://anchor.fm/practicingpolya/support

Join Erin and Michelle as they cover another topic contributing to the pain epidemic in our world - medical imaging. We've all likely heard a story of someone having an x-ray or MRI and being told, “you have the spine of a 80 year old” or “this is the worst thing I've seen, I can't believe you're not in more pain”. This type of language is harmful and can actually impact an individual's progress and prognosis! Imaging is an important tool in healthcare to prevent and diagnose serious disease or pathology, but it can be overused and used in the wrong situations which can sometimes lead to poorer outcomes for someone. Michelle and Erin want you to be aware of when medical imaging is helpful and when it might not be necessary, so that you can continue to be the best advocate for yourself. References: - Brinjikji, W., Luetmer, P. H., Comstock, B., Bresnahan, B. W., Chen, L. E., Deyo, R. A., … Jarvik, J. G. (2015). Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. American Journal of Neuroradiology, 36(4), 811–816. https://doi.org/10.3174/ajnr.A4173 - Deyle, G. The role of MRI in musculoskeletal practice: a clinical perspective. Journal of Manual and Manipulative Therapy 2011;19(3): 152-161. - Babineau, E. (2018, August 2). Imaging – Does it actually paint a clearer picture? Motion. https://motion.care/imaging-does-it-actually-paint-a-clearer-picture/. - Fernandez, E. (2021, April 28). Medical Imaging Rates Continue to Rise Despite Push to Reduce Their Use. Medical Imaging Rates Continue to Rise Despite Push to Reduce Their Use | UC San Francisco. https://www.ucsf.edu/news/2019/09/415286/medical-imaging-rates-continue-rise-despite-push-reduce-their-use. - Flynn, T. W., Smith, B., & Chou, R. Appropriate Use of Diagnostic Imaging in Low Back Pain: A Reminder That Unnecessary Imaging May Do as Much Harm as Good. Journal of Orthopaedic & Sports Physical Therapy 2011;41(11): 838-846. - Jensen M.C., Brant-Zawadzki M.N., Obuchowski N., Modic M.T., Malkasian D., Ross J.S. Magnetic resonance imaging of the lumbar spine in people without back pain. New England Journal of Medicine 1994;331:69–73. - Radiation Dose in X-Ray and CT Exams. (2019, July 1). Radiologyinfo.org. https://www.radiologyinfo.org/en/info/safety-xray#:~:text=Like%20other%20sources%20of%20background,part%20of%20our%20daily%20living. Disclaimer: This podcast contains general information for community education purposes only, and does not take into account your specific comorbidities that your current healthcare provider may be managing. Please contact your care provider with questions regarding anything particular to you.

In this Giants of Cardiothoracic Surgery interview, Joel Dunning speaks with Oscar Howard “Bud” Frazier about his career. Dr Frazier trained with Michael DeBakey and Denton Cooley while they were developing the first mechanical heart. He continued and advanced this work throughout his career while also performing over 1,200 heart transplants and over 500 left ventricular assist devices (LVAD). Dr Frazier also performed the first HeartMate implantation and the first Jarvik implantation. He has been an instrumental part of mechanical heart development and continues to take a close interest in this rapidly advancing field.

1) Depresión Sonora - "Ya no hay verano" Instagram: @depresion.sonora 2) Lust Era - "Largas horas" Instagram: 3) .Stendal - "Jarvik 7" Instagram: @puntostendal 4) Ramas Rotas - "Aunque todo parezca" Instagram: @ramasrotas 5) LPM - "Postal de nada" Instagram: @somoslpm 6) White Interface - "As if We Care" Instagram: @whiteinterface 7) Camile - "¿EL beso?" Instagram: @gonzaleznavaja_ 8) Woosh - "No Name" Instagram: @the_woosh 9) Valgur - "Zapandú" Instagram: @soyvalgur 10) Aleex Raptor - "Vanguardistas" Instagram: @aleexraptor 11) Los Gigantes - "La remera de Walter TV" Instagram: @nolorulz 12) Cianuropolis - "2012" Instagram: @cianuropolis_ 13) Sin Calorías - "Universidad" Instagram: @sin_calorias_band 14) Amar Go - "Recuerdos" Instagram: @amar_goband

Dr Carolyn Lam:                Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. This week's issue provides much long awaited healthcare resource utilization and cost implications in the MOMENTUM 3 randomized controlled trial of a magnetically levitated cardiac pump in advanced heart failure. All of this coming right up after these summaries.                                                 The first original paper this week provides important mammalian data on the acute effects of phosphodiesterase type 1 inhibition on the heart. Now phosphodiesterase type 1, or PDE1, is known to hydrolyze cyclic AMP and cyclic GMP in the heart. However, what's important to understand is that data from rodents may not be applicable to humans because rodents express mostly the cyclic GMP favoring PDE1A isoform, whereas human hearts predominantly express PDE1C isoform which has a balanced selectivity for cyclic AMP and cyclic GMP.                                                 In today's paper, first author Dr Hashimoto, corresponding author Dr Kass from Johns Hopkins University School of Medicine and colleagues, determined the acute effects of PDE1 inhibition on PDE1C expressing mammals, dogs and rabbits, in normal and failing hearts. They found that selective inhibition of PDE1 with ITI-214 induced positive inotropic, lusitropic, chronotropic, and arterial vasodilatory effects in dogs and rabbits. These effects occurred via cyclic AMP modulation and were observed in failing hearts. ITI-214 contractile increase was insensitive to beta adrenergic blockade or heart rate increase, but inhibited in vivo by adenosine receptor inhibition. Furthermore, isolated myocytes revealed differences between PDE1 and PDE3 inhibition. Wherein PDE3 inhibition, augmented beta receptor agonism and calcium transients, whereas PDE1 inhibition enhanced function without calcium increase. These findings have important clinical implications for ITI-214 which has completed phase 1 trials and may provide a novel therapy for heart failure.                                                 We know that macrophages are involved in foam cell formation in atherosclerotic plaques, but our next paper tells us we may now have a way to therapeutically modify this. Co-corresponding authors Dr Wei and Schober from Ludwig Maximilian's University Munich elucidated the role of microRNA generating enzyme Dicer in macrophage activation during atherosclerosis. They showed that Dicer deletion in macrophages accelerated atherosclerosis in mice, along with enhanced inflammatory response and increased lipid accumulation in lesional macrophages. In vitro, alternative activation was limited, whereas lipid filled foam cell formation was exacerbated in Dicer deficient macrophages due to impaired mitochondrial fatty acid oxidative metabolism. MicroRNA biogenesis promoted the degradation of fatty acids by mitochondrial respiration in macrophages, which in turn reduced intracellular lipid storage and limited atherosclerosis. Thus, reducing foam cell formation in atherosclerotic arteries by enhancing energy metabolism through microRNA mediated fatty acid oxidation may be a promising approach for the treatment of atherosclerosis.                                                 The next study evaluates how aortic stiffening relates to resting cerebral blood flow and cerebral vascular reactivity in older adults. First and corresponding author Dr Jefferson from Vanderbilt Memory and Alzheimer's Center and her colleagues studied participants free of clinical dementia, stroke, or heart failure, including 155 older adults with normal cognition and 115 mild cognitive impairment. They found that greater thoracic aortic stiffening quantified by cardiac magnetic resonance was associated with lower cerebral blood flow in cognitively normal older adults. Aortic stiffening was associated with reduced resting cerebral blood flow in the presence of preserved reactivity and associated vasodilatory capacity, particularly among participants without hypertension. ApoE4, a well-known genetic susceptibility risk factor for Alzheimer's disease, modified the results with stronger effects among carriers in the temporal lobes, where Alzheimer's disease pathology is known to first evolve. In summary, greater aortic stiffening related to lower regional cerebral blood flow and higher cerebral vascular reactivity in cognitively normal older adults, especially among individuals with increased genetic predisposition for Alzheimer's disease. Understanding the association between higher aortic stiffness and compromised brain health, including cerebral hemodynamics, may allow for earlier detection and targeted interventions to prevent or mitigate the onset of more serious cerebral vascular damage associated with greater aortic stiffening.                                                 Aortic valve replacement for aortic stenosis is usually timed according to the development of symptoms, but could the timing be too late once irreversible myocardial scar has developed? Co-first authors Drs Musa and Treibel, corresponding author Dr Greenwood from University of Leeds and their colleagues found that in patients with severe aortic stenosis, focal myocardial fibrosis determined by cardiac magnetic resonance imaging was present in over 50% of patients and was associated with a two-fold higher late mortality. Focal scar was independently associated with all cause and cardiovascular mortality, after both surgical and transcatheter aortic valve replacement. In severe aortic stenosis, late gadolinium enhancement appears to be a useful biomarker of left ventricular remodeling, and its presence is associated with worse long-term outcomes following aortic valve intervention. Thus, in severe aortic stenosis, late gadolinium enhancement may be a useful biomarker of left ventricular remodeling, and its presence may be associated with worse long-term outcomes following aortic valve intervention.                                                 The next study suggests that endogenous factor Xa activity may be irrelevant pharmacodynamic marker to guide Edoxaban dosing in future. First author Dr Yin, corresponding author Dr Giugliano from TIMI Study Group, Brigham and Women's Hospital in Boston, and their colleagues, describe the value of endogenous factor Xa activity as a pharmacodynamic marker, linking Edoxaban concentrations and clinical outcomes in the ENGAGE AF-TIMI 48 trial. They showed that the extent of inhibition of endogenous factor Xa activity was influenced by Edoxaban dosing and clinical characteristics, and was associated with both antithrombotic benefit and risk of bleeding. The implications are that this approach of linking endogenous factor Xa activity to clinical outcomes may be used to guide dose selection in future clinical trials, to monitor patients in certain clinical scenarios, or to define the doses of oral factor Xa inhibitors in patients who require precise anticoagulation therapy.                                                 The next paper describes a novel multi-protein complex that plays a critical role in regulating cardiomyocyte survival. First author Dr Zhang, corresponding author Dr Yan from University of Rochester School of Medicine and Dentistry and colleagues, showed that phosphodiesterase 1C is activated by transient receptor potential canonical channel-3 derived calcium, thereby antagonizing adenosine A2 receptor cyclic GMP signaling and promoting cardiomyocyte death or apoptosis. Targeting these molecules individually, or in combination, may represent a compelling therapeutic strategy for potentiating cardiomyocyte survival.                                                 The final paper demonstrates a molecular link between two well-recognized biomarkers of fibrosis, Galectin-3 and Osteopontin. First author Dr Shirakawa, corresponding author Dr Sano from Keio University School of Medicine and their colleagues, showed that Osteopontin was almost exclusively produced by Galectin-3 high CD206 positive macrophages, which specifically appear in the infarct myocardium after a myocardial infarct. The interleukin-10-STAT3 Galectin-3 axis was essential for Osteopontin producing reparative macrophage polarization after myocardial infarction, and these macrophages contributed to tissue repair by promoting fibrosis and clearance of apoptotic cells. These results therefore suggest that Galectin-3 may contribute to reparative fibrosis in the infarct myocardium by controlling Osteopontin levels. And that brings us to the end of this week's summaries, now for a feature discussion.                                                 Left ventricular assist devices have truly revolutionized our management of advanced heart failure. In fact, these devices have allowed us to keep patients not just as a bridge to transplantation, but as destination therapy. The devices get better and better but also more and more expensive, and the problem is, that places a lot of strain on our healthcare systems. A lot of us are crying out for information on the cost effectiveness of these newer devices, and guess what? We have answers this week with our featured paper.                                                 I am delighted to have with us the first and corresponding author Dr Mandeep Mehra from Brigham and Women's Hospital in Boston, Massachusetts, as well as our senior editor Dr Biykem Bozkurt from Baylor College of Medicine in Houston, Texas. Hello, Mandeep and Biykem! I am so pleased to be talking about a subject really close to all our hearts. Mandeep, could you start by maybe sketching out the actual issue, and maybe reminding our audience what's the difference between the different types of left ventricular assist systems that you compared. Dr Mandeep Mehra:       The era of left ventricular assist devices took a major therapeutic shift when we recognized that we could usher in continuous flow devices. These are devices that generate no peripheral pulse, they do not have systole and diastole. And these devices are small in profile, have very few moving parts, and there are several commercially available devices, two in the United States and up to three worldwide, that bear these characteristics.                                                 The HeartMate II device, which is a continuous flow device that flows blood in an axial format. The HeartWare, or HVAD device, which is a centrifugal flow pump, where the blood comes in and then is ejected at a 90 degree angle. The Jarvik 2000 pump that is still used in some areas, in many regions experimentally, and then the new kid on the block, the HeartMate 3 device, which is a centrifugal flow pump with some very unique technological characteristics. Dr Carolyn Lam:                Nice! And now drumroll, please tell us what you found in your brilliant study this week. Dr Mandeep Mehra:       First, I'd like to remind the audience that the MOMENTUM 3 trial which randomized patients to the HeartMate II versus the HeartMate 3 device, was called MOMENTUM 3 and was a two-year study. We presented the pivotal two year trials results in 366 randomized patients earlier this year in The New England Journal of Medicine, and this study showed that the HeartMate 3 was superior on the primary endpoint when compared to the HeartMate II. The primary endpoint was survival, free of a disabling stroke, or the need to replace the pump surgically for a pump malfunction. And much of that, Carolyn, was driven by the need for replacement of the pump because the HeartMate 3 pump has some unique features that reduce its proclivity for pump thrombosis.                                                 The HeartMate 3 pump is a frictionless pump. It's completely, magnetically, dynamically, born in the rotor. It has wider blood flow paths, so we don't see hemolysis with this pump. And this pump also has an artificial intrinsic pulse that has been created, that pulsates the pump in a 40 beats per minute configuration. So this was the primary trial result, and one of the lucky foresights that we had when we designed the trial was to embed, prospectively, economic analysis within this trial. We recognized that the cost effectiveness related issues and cost configurations with these devices would become very, very important as we scale into today's day and age of healthcare transformation. And the paper that is being presented in Circulation this week, really speaks to the health resource utilization and cost outcomes between the two devices.                                                 We found that the HeartMate 3 pump is actually a cost minimization device, and what that means, Carolyn, is that we have become very used to thinking of new technology as providing incremental costs. So we think that, "Oh, well, what incremental costs should society bear for the benefits as we allocate new technology?" And in this particular trial, what we found is that while the costs of the pump itself, the HeartMate II and the HeartMate 3, were kept the same, which means its operational implant costs were the same, pretty much. We found that the HeartMate 3 pump was associated with a reduction in healthcare resource utilization over two years and with a marked decrease in cost. And in fact, our estimate of cost reduction was in the range of about 65 thousand dollars less, compared to the HeartMate II, in favor of the HeartMate 3. Dr Carolyn Lam:                Wow, Mandeep, first of all, congratulations on these remarkable findings. Biykem, I really have to bring you in here. What do you think of the implications of this? Dr Biykem Bozkurt:         First, I would like to congratulate the authors for a very innovative approach. As Mandeep has stated, they prospectively collected very challenging billing data from the hospitals, and then also did a very complex analysis including the VRG, as well as looking at payer reimbursements for public versus private. And did a variety of subgroup analysis, which I thought was quite helpful in sorting out that perhaps the cost effectiveness was concurrent both from the Medicare, the public, as well as the private, or regardless of the intent for destination versus bridge to transplant.                                                 Probably the most important concept when you look at these close analysis is incremental cost effectiveness ratio, per quality of adjusted life year gained. Now, I do realize the current analysis doesn't allow us to infer the ICER benefit or the incremental cost effectiveness, which I think the investigators are planning to do with a thousand and more patients over a course of two years, which is going to be probably the more definitive. But as it currently stands, with what is provided by Dr Mehra and his colleagues is, we're probably reaching that sweet spot of what is construed as the cost effectiveness ratio of a cost.                                                 Let's say 100 thousand dollars over the course of a year, then I would like to ask Mandeep whether on the prediction will reach that threshold of less than 100 thousand dollars. Because the former studies, looking at the ICER ratios, or incremental cost effectiveness ratios for the DT destination therapies, usually we select somewhere around 200 thousand dollars. And I know that usually that is seen as a prohibited cost, and there was a discussion whether we would be able to reduce the cost by about half, either doing index admission and add subsequent hospitalizations. With the data Dr Mehra and his colleagues have shown, it looks like the re-hospitalization cost is about, approximately half, or reduced by 50%. Mandeep, any thoughts on that, on that sweet spot? Dr Mandeep Mehra:       Yeah. I think, Biykem, you have articulated this extraordinarily well. And for the audience, since it's worldwide, I'd like to place a few things in perspective on how to think of economic modeling. First of all, the point I would make is that this is the first prospectively collected data that we have in the field, and as you pointed out, it was very, very difficult to pull this data together and is still very complex. But let's just think about what ICER really is. It all starts with what we consider to be health utility.                                                 For example, Carolyn, Biykem, and me less so, would have a health utility of 1.0, 1.0 means a perfect health utility number. And I know, Carolyn, you and Biykem are absolutely perfect so you would be a 1.0, I probably am not a 1.0. But a patient with advanced heart failure has a health utility of about .4, so that's only 40% of what is perfect. And when we place ventricular assist devices, whether you place the HeartMate 3 or the HeartMate II, the health utility actually jumps up to about .7. So it's not perfect yet, but it moves all the way up there.                                                 The incremental cost effectiveness ratios of implanting a device over time are calculated based on this health utility benefit, compared to the population of advanced heart failure. And the best current estimates of the HeartMate II are that ICER is about 200 thousand dollars, per quality adjusted life years gained, and this has been done by creating what's known as Markov modeling. A lot of that, by the way, is conjecture, it's not real information. It is predicted information, so one has to take that data with a grain of salt.                                                 Here in this health resource analysis for MOMENTUM 3, we actually looked at actual data. There are some estimates used in this analysis as well, where we did not have accurate billing forms available, but we focused on those things where we had very clear knowledge of the cost of outcomes. For example, we did not look at the costs of outpatient follow-up care. We mainly looked at the cost differences of hospitalizations. And what we essentially found here is that just looking at hospitalizations and differences between the two devices, the cost differential, whether it's Medicare which is public [inaudible 00:20:14], or whether it's commercial. It ranges somewhere between 50 to 65 thousand dollars of difference between the two devices.                                                 Now, if you assume that the ICER for the HeartMate II is accurately at about 200 thousand, and you reduce that ICER by about 50 to 60 thousand, the ICER would naturally come into the range of what you would consider to be about 135 thousand to 150 thousand dollars per quality adjusted life years gained for the HeartMate 3, compared to an advanced heart failure population. Once we look at it from that perspective, as Biykem pointed out, we are getting closer and closer to the societal norms.                                                 At one time-point, society used to think of a quality adjusted life years gained cost of 50 thousand dollars as something that would be acceptable to society, and this was seemingly based on the threshold for what dialysis provides in benefit. And now, we recognize that we have to really expand that to somewhere around 100 thousand more logically, or between 100 and 150 thousand for some technologies. The important thing I would say to you is that, that is society dependent. So what the United States considers to be a reasonable ICER, say 100 to 130 thousand dollars per quality adjusted life years gained, may not be the same that Great Britain would look at, or Sweden would look at, or another country would look at. And each country actually creates their own economic value propositions, and this will have to be taken into account as we think about this data as well. Dr Carolyn Lam:                How cleverly and clearly articulated, thank you so much Mandeep. Just one last question for both you and Biykem, what do you think this implies for moving to less and less advanced heart failure with these left ventricular assist device systems? Biykem? Dr Biykem Bozkurt:         It's an ever-expanding field, and as these devices are becoming smaller, lower profile with lesser complications and more affordable, probably the utilization will likely increase as we have been seeing. As you know, even the percutaneous non-durable device used, as well as our mechanical circulatory support durable devices are definitely increasing utilization. And thus, one may wonder not only the bridge to transplantation, but the destination therapy portfolio, or bridge to decision portfolio, may really increase as these devices become safer and more affordable. Dr Carolyn Lam:                Wow, that's amazing. How about you, Mandeep, what do you think? Dr Mandeep Mehra:       Carolyn, I couldn't have said it any better than what Biykem articulated. I do think that at least in the United States, as we reach the thresholds of cost effectiveness that we as a society accept, we will start to see a lot more widespread utilization, particularly for lifelong therapy or so-called destination therapy. I completely agree with that. I think that moving the needle to the less sicker population is still challenging, because there are complications with these devices that make that slightly difficult.                                                 There was a trial called the REVIVE-IT trial that was stopped midstream largely because of concerns about pump thrombosis, and that trial was looking at taking these devices to a less sick NYHA class 3 population and was stopped midstream. Now that the HeartMate 3 has pretty much resolved the issue of pump thrombosis, and even show a halfing in stroke rates with this device over two years, I think that that portfolio of evidence needs to be reopened. I would caution though, that until we have confirmatory randomized data in those less sick populations, the use to that population should still stay restricted. Dr Carolyn Lam:                I don't think anyone could have said it better than both of you. Thank you so much for this very insightful and balanced conversation.                                                 Thank you so much for listening today. You were listening to Circulation on the Run, and don't forget to tune again next week.  

We've reached our 25th episode and, to mark it, we look at one of the shows oddities, Jarvik. We also stop and check on our Top 5 characters so far. Check out more from Eric on the world of movie and television special effects in the NEOZAZ series Effectively Speaking! Follow NEOZAZ on social media at Facebook, Twitter, and Instagram. Blakes 7 In Character and all the work we do at NEOZAZ is funded solely by the generosity of Patreon Supporters. To learn how you can help support these shows and get access to exclusive shows, specials and productions produced exclusively for our supporters, visit patreon.com/neozaz. Support starts as low at 1 dollar a month and each pledge goes into keeping all our past and present work online as well as helping us continue to grow and create new shows for the future.

Hello and welcome to the Spinal Hygiene Movement! We are a group of Chiropractors, Physicians, health care professionals of all kinds, and people who are trying to bring spinal health to light in a world of damaging posture, and sedentary lifestyles! To learn more visit http://www.HomeSpinalCare.com or if you are a Health Care Professional yourself please visit http://www.SpinalHygieneMovement.com to find out how you can join the movement! References: Brinjikji, W., Luetmer, P. H., Comstock, B., Bresnahan, B. W., Chen, L. E., Deyo, R. A., ...Jarvik, J. G. (2014). Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. American Journal of Neuroradiology, 36(4), 811-816. Shock Over Disc Degeneration in 10‐Year Olds (n.d.). Retrieved May 11, 2017, from http://journals.lww.com/backletter/Citation/2004/01000/Shock_Over_Disc_Degeneration_in_10_Year_Olds_But.1.aspx

Interview with Jeffrey G. Jarvik, MD, MPH, author of Association of Early Imaging for Back Pain With Clinical Outcomes in Older Adults

Calendar In 2 decembrie 1982 dr William C DeVries a facut primul interventie cu scopul de a implamnta Jarvik-7, o inimă artificială. Pericolele lipsei de scepticism Cautatori de fantome (drogati) dau foc unei case http://www.fox8live.com/story/24042103/historic-lebeau-plantation-burns-to-the-ground-in-old-arabi http://www.realitatea.net/s-a-impuscat-in-timp-ce-spargea-nuci-cu-pistolul_1324965.html Subiecte tratate cu scepticism Momente de creație = erori logice, dezinformare și distorsiuni http://www.creationmoments.com/radio Chemtrails! http://www.dataasylum.com/mindcontrol-chemtrails-summary.html Un vierme gigantic ...continue reading "Sceptici în România – Episodul 81"

They're back! After a month off due to the death and resurrection of Dave's computer, the Shake and Blake boys return in a blaze of glory! In "The Harvest of Kairos," Tarrant plans some piracy but is unprepared for his old mentor Jarvik, who wins both the Liberator and Servalan's affections. In "The City at the Edge of the World," Vila gets more than he bargained for when the notorious Bayban the Butcher hires him to open an impregnable room. Plus, the Who count finally notches up a Doctor, Jarvik is hailed as the ultimate man, and Dave channels Ian's former co-host.

They're back! After a month off due to the death and resurrection of Dave's computer, the Shake and Blake boys return in a blaze of glory! In "The Harvest of Kairos," Tarrant plans some piracy but is unprepared for his old mentor Jarvik, who wins both the Liberator and Servalan's affections. In "The City at the Edge of the World," Vila gets more than he bargained for when the notorious Bayban the Butcher hires him to open an impregnable room. Plus, the Who count finally notches up a Doctor, Jarvik is hailed as the ultimate man, and Dave channels Ian's former co-host.

They're back! After a month off due to the death and resurrection of Dave's computer, the Shake and Blake boys return in a blaze of glory! In "The Harvest of Kairos," Tarrant plans some piracy but is unprepared for his old mentor Jarvik, who wins both the Liberator and Servalan's affections. In "The City at the Edge of the World," Vila gets more than he bargained for when the notorious Bayban the Butcher hires him to open an impregnable room. Plus, the Who count finally notches up a Doctor, Jarvik is hailed as the ultimate man, and Dave channels Ian's former co-host.

They're back! After a month off due to the death and resurrection of Dave's computer, the Shake and Blake boys return in a blaze of glory! In "The Harvest of Kairos," Tarrant plans some piracy but is unprepared for his old mentor Jarvik, who wins both the Liberator and Servalan's affections. In "The City at the Edge of the World," Vila gets more than he bargained for when the notorious Bayban the Butcher hires him to open an impregnable room. Plus, the Who count finally notches up a Doctor, Jarvik is hailed as the ultimate man, and Dave channels Ian's former co-host.

Tue, 26 Jul 2011 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/13288/ https://edoc.ub.uni-muenchen.de/13288/1/Liebermann_Anja.pdf